NASH trials recruiting in Missouri

All NASH trials nationally

Cities in Missouri

Recruiting trials in Missouri

• A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
  NCT07221188 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Missouri: Springfield, St Louis
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Missouri: Kansas City
• A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
  NCT07221227 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Missouri: Kansas City, Springfield, St Louis
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
  NCT05519475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Missouri: St Louis
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
  NCT06528314 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Missouri: Columbia, Kansas City, St Louis
• A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  NCT06215716 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Missouri: Columbia, Kansas City, St Louis
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Missouri: St Louis
• A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
  NCT06920043 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Missouri: Kansas City
• A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
  NCT07288138 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Missouri: Columbia, St Louis
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
  NCT06419374 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Missouri: St Louis
• Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
  NCT06335771 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · Missouri: Columbia
• Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
  NCT06571474 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: All (male and female) · Missouri: Columbia
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
  NCT06632457 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Missouri: Columbia, Kansas City
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Missouri: Chesterfield, Columbia, Kansas City
• Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
  NCT05526144 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Missouri: Columbia